


DuoBody Technology:

- Builds on **insights** from the **natural biology of antibodies**¹
- Employs controlled **Fab-arm exchange**^{1,2} to generate **stable bispecific antibodies**¹ with:



Natural IgG1 Structure¹



Half-lives similar to natural antibodies¹



Regular effector functions¹

DuoBody Technology is based on the **naturally-occurring** process of **Fab-arm exchange**.¹

It can generate dual-targeting antibodies from parent IgG monoclonal antibodies **against any pair of targets**.¹⁻³



Two 'parent' monoclonal antibodies, each specific to one of the two desired targets, are produced and purified separately.^{1,2}



Single matched point mutations introduced in the CH3 domains of these antibodies favor heterodimerization.¹⁻³



In-vitro reduction allows 'parent' antibody homodimers to dissociate.^{1,2}



Upon re-oxidation, heterodimer formation facilitated by the CH3-domain mutations produces a stable, bispecific antibody.¹⁻³

DuoBody Technology is **distinct** from other dual-targeting technologies.²

Chain pairing is accomplished with **minimal protein engineering** using only **one point mutation**.¹⁻³

Efficient screening and discovery allows generation and screening of **large libraries**⁴ of bispecific antibodies, and can be applied to production at **commercial manufacturing scale**.³

DuoBody Technology is the basis of **11 bispecific antibody therapies**.^{5,6}



DuoBody Pipeline

Hematology

Epcoritamab^a
(DuoBody-CD3xCD20)

Indication	Phase
R/R DLBCL	3
R/R FL	3
First line DLBCL	3
First line FL	3
B-cell NHL	2
First line DLBCL	2
R/R DLBCL and cFL	2
R/R CLL and Richter's Syndrome	1/2
B-cell NHL	1/2
R/R B-cell NHL	1/2
R/R aggressive B-cell neoplasms (Pediatric)	1

GEN3017
(DuoBody-CD3xCD30)

R/R classical HL and TCL	1/2
--------------------------	-----

Solid Tumors

Acasunlimab
(DuoBody-PD-L1x4-1BB)

NSCLC	3
NSCLC	2
Solid tumors	1/2
Solid tumors	1

GEN1042/BNT312^b
(DuoBody-CD40x4-1BB)

Solid tumors	1/2
Solid tumors	1

GEN1047
(DuoBody-CD3xB7H4)

Solid Tumors	1/2
--------------	-----

GEN1057
(DuoBody-FAPα×DR4)

Solid Tumors	1
--------------	---

GEN1059/BNT314^b
(DuoBody-EpCAMx4-1BB)

Solid Tumors	1/2
--------------	-----

cFL, classic follicular lymphoma; CLL, chronic lymphocytic leukemia; DLBCL, diffuse large B-cell lymphoma; FL, follicular lymphoma; HL, Hodgkin lymphoma; NHL, non-Hodgkin lymphoma; NSCLC, non-small cell lung cancer; R/R, relapsed/refractory; TCL, T-cell lymphoma.

The safety and efficacy of investigational agents and/or investigational uses of approved products have not been established. There is no guarantee any compound and/or use will be approved by any health authority for commercialization.

^aEpcoritamab – 50:50 partnership with AbbVie Inc. ^bDuoBody-CD40x4-1BB, DuoBody-EpCAMx4-1BB – 50:50 partnership with BioNTech.

Learn more about DuoBody Technology



Click the icon or scan the QR code to listen to a podcast on the DuoBody Technology platform.



Click the icon to view a short video of the DuoBody Technology platform.

1. Labrijn AF, et al. *Proc Natl Acad Sci USA*. 2013;110:5145-50. 2. Labrijn AF, et al. *Nat Protoc*. 2014;9:2450-63. 3. Gramer MJ, et al. *MABS*. 2013;5:962-73. 4. Neijssen J, et al. *J Biol Chem*. 2021;296:100641. 5. Global Pipeline: Genmab. Genmab.com. <https://www.genmab.com/pipeline/>. Accessed October 30, 2024. 6. Data on file, Genmab U.S., Inc.